Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ponatinib in advanced or metastatic medullary thyroid cancer
NCT01838642Phase 2Terminated
- Sponsor
- National Institutes of Health
- Start
- Mar 2013
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ponatinib in Medullary Thyroid Cancer (MTC), sponsored by National Institutes of Health. Started Mar 2013; status: terminated.
02
Drugs
ponatinib
03
Conditions
Medullary Thyroid Cancer (MTC)
Beyond the preview
Go deeper on NCT01838642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01838642.